In his Kavli Foundations in Chemistry Lecture at the 244th meeting of the American Chemical Society (ACS), Robert Langer, Sc.D., discussed a material that mimics vocal cords. Langer heads a team of over 100 in laboratories at the Massachusetts Institute of Technology. From the Aug. 20, 2012 news release on EurekAlert,
The artificial vocal cord material, the first designed to restore lost flexibility in human vocal cords, results from an ongoing effort to produce artificial tissues in the lab, Langer explained. Lost flexibility in the vocal cords, due to the effects of aging or disease, is a major factor in the voice loss that affects 18 million people in the United States alone.
“The synthetic vocal cord gel has similar properties as the material found in human vocal cords and flutters in response to air pressure changes, just like the real thing,” explained Langer, who is the David H. Koch Institute Professor at MIT.
The vocal cords are two folds in the “voice box” that vibrate, or come together and away from each other very quickly to produce puffs of air that help form sounds. They function in much the same way as a reed in a saxophone. The cords consist of layers of muscle, ligament and a membrane. A layer between the ligament and the membrane is very flexible, and that flexibility and pliability is critical for speech.
But when someone, such as a teacher, a politician or a performer, overuses their voice, scar tissue develops. The same thing happens when a person gets older, accounting for the lower volume and hoarseness often apparent in older people. Cancer or having a tube inserted in the throat for medical procedures also can damage the cords. Scar tissue is stiff, and scarring leaves a person with a hoarse, breathy voice.
“About 90 percent of human voice loss is because of lost pliability,” said Steven Zeitels, M.D., F.A.C.S., Langer’s collaborator on the project. Zeitels is the Eugene B. Casey Professor at Harvard Medical School and Director of the Massachusetts General Hospital Voice Center. His patients include singers Julie Andrews of The Sound of Music fame, who lost her full vocal range after surgery done elsewhere in 1997, Steven Tyler of Aerosmith and Adele. “I recognized this need in my practice over the years, after seeing many patients with voice problems. I went to Bob Langer because I knew he could help design a material that would ultimately help patients speak and sing again. Currently, no treatments exist to restore vocal cord flexibility.”
The material had to be very flexible and be able to vibrate just like human vocal cords. After trying numerous candidates, Langer’s team settled on polyethylene glycol 30 (PEG30), which is already used in personal care creams and in medical devices and drugs approved by the U.S. Food and Drug Administration (FDA), as a starting material and created polymers based on it. The PEG30 gel can flutter at a rate of 200 times per second, which is a normal rate for a woman speaking in a conversation.
Here’s a video which shows the gel and introduces you to some of the scientists working on this project accompanied by a soundtrack of Julie Andrews singing prior to her 1997 operation,
Here’s how the gel would work based on animal testing results (from the news release),
A physician would inject the gel into a patient’s vocal cords. Patients would receive different formulations, depending on how they use their voices. The most stable version is highly “cross-linked,” which means the molecules of PEG are more tightly stitched together than in other versions. That makes the material a little bit rigid, but it would still help restore someone’s speaking voice. A singer, however, would likely receive a formulation that is more loosely stitched together, or less cross-linked, which is more flexible to allow the patient to hit high notes. The gel degrades over time, so patients would receive two to five injections per year, estimated Zeitels.
Tests in animals suggest that the material is safe, and human trials will hopefully begin in mid-2013. Some of Zeitels’ patients, such as Andrews, have formed a nonprofit organization called The Voice Health Institute, which funds Langer and Zeitels’ research on the vocal cord biomaterial.
I looked at the Voice Health Institute (VHI) website and found this on the About Us page (Note: I have removed some links),
The Voice Health Institute (VHI) is a federally-approved non-profit organization (501-C-3) that was established in 2003 by patients with voice loss to advance voice restoration and breathing impairment as a result of throat and larynx problems through the support of innovative research, education and outreach programs. A small group of patients from around the United States convened in New York City to share their experiences with throat and larynx cancer, vocal cord paralysis and voice loss. These patients shared their gratitude to the caregivers at the Massachusetts General Hospital while acknowledging substantial frustration with their initial management.
This highlighted the wide disparity of care offered in the United States and abroad and the generalized limited awareness of the general public about issues related to the throat, larynx and voice. Julie Andrews, the iconic singer/actress who lost her singing voice joined the VHI at its incorporation as the Honorary Chairwoman through the efforts of Dr. Steven Zeitels, her current physician and surgeon. Since then, iconic rock vocalists Steven Tyler of Aerosmith and Roger Daltrey of The Who have also provided invaluable support to the VHI to forward their mission.
The VHI has funded educational and award-wining pioneering research programs at:
- Massachusetts General Hospital
- Harvard Medical School
- Massachusetts Institute of Technology
- Boston University
- University of South Carolina
- American Speech-Language-Hearing Association (ASHA)
- New England Conservatory of Music and
- American Broncho-Esophagological Association (ABEA)
I don’t see a lot of doctors or researchers on either the ‘working’ board which features mostly business people (Julie Andrews is the honorary chair and the six business people are all male) or the advisory board (broadcasters or singers and a better gender balance [eight members, two of whom are female]). I wonder how they decide the disbursements if neither sets of board members have medical expertise. Presumably they convene a special committee to oversee grant submissions but who’s on the committee? In a research area that’s so highly specialized all of the players are likely to know each other. So, the people adjudicating the disbursements this time may be applying for research funds the next time and presenting their submissions to the last round’s applicants who are now the adjudicators.
The problem which all organizations that disburse funds face is this: if you stack committees with people who don’t have expertise in the specialty you may find they don’t understand the proposed research well enough to make informed decisions or if they are experts in the field everyone is beholden to everyone else.
Enough of this excursion into the business of funding. Langer’s work extends beyond this vocal cord research, from the news release,
Artificial vocal cords are just one artificial tissue in development in Langer’s lab. He described work on building intestinal, spinal cord, pancreatic and heart tissue in the laboratory with many different types of materials. Among them: Nanowires (which are about a tenth the diameter of a human hair) and something called “biorubber.”
“It’s hard to know when they will be ready for clinical use,” Langer said. “But In Vivo Therapeutics hopes to start clinical trials for the spinal cord tissue we’ve developed within the next year.”
Langer also recently developed a pacemaker-sized microchip that delivers just the right amount of medication at just the right time, potentially allowing thousands of patients to ditch painful needles forever. A clinical trial of the device, implanted in women with osteoporosis, has just concluded and showed that it was safe to use. The device released osteoporosis medication when it received a signal from a computer. It worked just as well as daily shots of the drug. MicroCHIPS, Inc., a company that Langer co-founded, will commercialize the remote-controlled microchip.
Another way to make medicines more effective is to make sure they go exactly to the location where they are needed; this reduces harmful side effects. Langer’s targeted nanoparticles can do just that. A clinical trial run by BIND Biosciences, another company co-founded by Langer, recently found that these nanoparticles are safe in humans. The particles have a homing molecule on them that targets them to prostate cancer cells or cancer blood vessels, and they deliver an anti-cancer medication called docetaxel. All of the materials, including the drug, are already approved by the FDA.
I expect that as the 244th meeting of ACS continues there’ll be more news about chemistry and the glorious future we can look forward to due to research. I hope they’re planning a few sessions that are less laudatory to balance things out.